Samantha Semenkow
Stock Analyst at Citi
(3.59)
# 2,166
Out of 4,516 analysts
209
Total ratings
49.4%
Success rate
4.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintained: Buy | $14 | $3.81 | +267.45% | 19 | Jun 30, 2026 | |
| IMVT Immunovant | Maintained: Buy | $57 → $61 | $39.88 | +52.96% | 16 | Jun 30, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $11 | $3.62 | +203.87% | 2 | Jun 15, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $33 | $17.83 | +85.08% | 2 | Jun 10, 2026 | |
| ROIV Roivant Sciences | Reiterated: Buy | $35 → $42 | $34.89 | +20.38% | 5 | May 21, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $151 | $68.30 | +121.08% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Maintained: Buy | $68 | $30.84 | +120.49% | 15 | May 13, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,152 | $862.93 | +33.50% | 19 | May 12, 2026 | |
| CPRX Catalyst Pharmaceuticals | Downgraded: Hold | $35 → $32 | $31.49 | +0.03% | 12 | May 7, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $64 → $97 | $102.07 | -4.97% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $24 | $5.91 | +306.09% | 4 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 | $1.90 | +110.53% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $17 | $14.86 | +14.40% | 6 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $39.87 | +15.37% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.20 | +243.75% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $136 → $142 | $109.58 | +29.59% | 2 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $19.96 | -69.94% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 | $49.62 | +101.53% | 5 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $52 | $22.70 | +129.07% | 9 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $3.55 | +238.03% | 14 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4.25 | $3.49 | +21.78% | 8 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.77 | +261.01% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $5 | $3.04 | n/a | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 → $4 | $31.47 | n/a | 8 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.7 → $0.75 | $0.00001 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $20.44 | n/a | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $7 | $5.30 | n/a | 2 | Jul 21, 2021 |
Larimar Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $14
Current: $3.81
Upside: +267.45%
Immunovant
Jun 30, 2026
Maintained: Buy
Price Target: $57 → $61
Current: $39.88
Upside: +52.96%
SAB Biotherapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $11
Current: $3.62
Upside: +203.87%
Cullinan Therapeutics
Jun 10, 2026
Reiterated: Buy
Price Target: $33
Current: $17.83
Upside: +85.08%
Roivant Sciences
May 21, 2026
Reiterated: Buy
Price Target: $35 → $42
Current: $34.89
Upside: +20.38%
Nektar Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $151
Current: $68.30
Upside: +121.08%
Beam Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $68
Current: $30.84
Upside: +120.49%
argenx SE
May 12, 2026
Reiterated: Buy
Price Target: $1,152
Current: $862.93
Upside: +33.50%
Catalyst Pharmaceuticals
May 7, 2026
Downgraded: Hold
Price Target: $35 → $32
Current: $31.49
Upside: +0.03%
Spyre Therapeutics
May 6, 2026
Rated: Buy
Price Target: $64 → $97
Current: $102.07
Upside: -4.97%
May 1, 2026
Rated: Buy
Price Target: $30 → $24
Current: $5.91
Upside: +306.09%
Apr 9, 2026
Rated: Buy
Price Target: $4
Current: $1.90
Upside: +110.53%
Apr 2, 2026
Maintained: Buy
Price Target: $14 → $17
Current: $14.86
Upside: +14.40%
Mar 31, 2026
Reiterated: Buy
Price Target: $46
Current: $39.87
Upside: +15.37%
Mar 23, 2026
Reiterated: Buy
Price Target: $11
Current: $3.20
Upside: +243.75%
Mar 20, 2026
Rated: Buy
Price Target: $136 → $142
Current: $109.58
Upside: +29.59%
Mar 20, 2026
Maintained: Sell
Price Target: $6
Current: $19.96
Upside: -69.94%
Mar 16, 2026
Reiterated: Buy
Price Target: $100
Current: $49.62
Upside: +101.53%
Mar 10, 2026
Maintained: Buy
Price Target: $15 → $52
Current: $22.70
Upside: +129.07%
Mar 4, 2026
Maintained: Buy
Price Target: $12
Current: $3.55
Upside: +238.03%
Nov 11, 2025
Maintained: Hold
Price Target: $5 → $4.25
Current: $3.49
Upside: +21.78%
Oct 10, 2025
Reiterated: Buy
Price Target: $10
Current: $2.77
Upside: +261.01%
Mar 6, 2025
Maintained: Buy
Price Target: $15 → $5
Current: $3.04
Upside: n/a
Jun 3, 2024
Initiated Coverage: Buy
Price Target: $6 → $4
Current: $31.47
Upside: n/a
May 18, 2023
Maintained: Hold
Price Target: $1.7 → $0.75
Current: $0.00001
Upside: n/a
May 11, 2023
Rated: Buy
Price Target: $130
Current: $20.44
Upside: n/a
Jul 21, 2021
Maintained: Buy
Price Target: $16 → $7
Current: $5.30
Upside: n/a